Summary
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in oversold territory now.
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m.
Enlivex Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,072 | $14,881.5 | $4,834.72 | -$10,046.78 | -67.51% |
 Sima Elimelech Activest Wealth Management | 67 | $1,420 | $298.82 | -$1,121.18 | -78.96% |
 Sean Reitenbach Prosperity Consulting Group LLC | 1,182.35 | $18,352.42 | $5,557.04 | -$12,795.38 | -69.72% |
 Bill McVay Red Tortoise LLC | 10.05 | $591 | $46.63 | -$544.37 | -92.11% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 0.07 | $0.93 | $0.31 | -$0.62 | -66.67% |
Enlivex Ltd. (ENLV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Enlivex Ltd. ever had a stock split?
Enlivex Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Oren Hershkovitz CEO | NASDAQ (CM) Exchange | M4130Y106 CUSIP |
| IL Country | 34 Employees | - Last Dividend | 9 Jul 2026 Last Split | - IPO Date |
Overview
Enlivex Therapeutics Ltd. operates as a pioneer in the space of clinical-stage macrophage reprogramming immunotherapy, focusing its efforts and resources on the development of groundbreaking treatments from its base in Ness Ziona, Israel. The company stands out in the biotech industry for its innovative approach towards addressing critical medical conditions through its extensive research and development activities. By targeting the body's innate immune system, specifically macrophages, Enlivex aims to introduce novel therapeutic solutions for diseases that currently have limited or no effective treatments.
Products and Services
- Allocetra for Sepsis-Induced Organ Dysfunction
Allocetra is Enlivex Therapeutics Ltd.’s flagship product, currently undergoing phase II clinical trials. This therapeutic candidate represents a significant advancement in the treatment of organ dysfunction caused by sepsis, a condition for which the available treatments are severely limited. Utilizing a unique mechanism that reprograms macrophages, Allocetra aims to restore immune homeostasis within the patient's body, potentially revolutionizing the treatment landscape for sepsis-afflicted individuals.
- Allocetra for Moderate Knee Osteoarthritis
In addition to its application for sepsis, Allocetra is being explored as a treatment option for moderate knee osteoarthritis. This exploration is at the phase I/II clinical trial stage, indicating promising preliminary results and the potential for Allocetra to address the inflammation and pain associated with this degenerative joint disease. By targeting the underlying immunological mechanisms within the knee joint, Allocetra could provide a novel therapeutic option for patients suffering from osteoarthritis.
- Allocetra for End-Stage Knee Osteoarthritis
Encouraged by the positive outcomes of previous studies, Enlivex is also extending the application of Allocetra to treat end-stage knee osteoarthritis. This study is in the phase I/II clinical trial period, focusing on a more severe form of the disease. The approach remains consistent, with the aim of leveraging macrophage reprogramming to alleviate symptoms and improve joint function in a patient demographic that typically has few viable treatment options outside of joint replacement surgery.
